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Abstract
Drug discovery is an extremely difficult and challenging endeavor with a very high failure rate. 
The task of identifying a drug that is safe, selective and effective is a daunting proposition because 
disease biology is complex and highly variable across patients. Metabolomics enables the 
discovery of disease biomarkers, which provides insights into the molecular and metabolic basis of 
disease and may be used to assess treatment prognosis and outcome. In this regard, metabolomics 
has evolved to become an important component of the drug discovery process to resolve efficacy 
and toxicity issues, and as a tool for precision medicine. A detailed description of an experimental 
protocol is presented that outlines the application of NMR metabolomics to the drug discovery 
pipeline. This includes: (1) target identification by understanding the metabolic dysregulation in 
diseases, (2) predicting the mechanism of action of newly discovered or existing drug therapies, 
(3) and using metabolomics to screen a chemical lead to assess biological activity. Unlike other 
OMICS approaches, the metabolome is “fragile”, and may be negatively impacted by improper 
sample collection, storage and extraction procedures. Similarly, biologically-irrelevant conclusions 
may result from incorrect data collection, pre-processing or processing procedures, or the 
erroneous use of univariate and multivariate statistical methods. These critical concerns are also 
addressed in the protocol.
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17.For high throughput NMR data collection, please refer to the Bruker ICONNMR manual to explore various configuration options. 
For example, composite experiments allow for the collection of multiple 1D and 2D experiments for the same metabolomics sample. 
An experimental set consisting of a 1D 1H, a 2D 1H-13C HSQC, and 2D 1H-13C HMBC experiment may be subsequently collected 
for the same sample before moving to the next sample in the queue.
18.It is imperative that NMR data are collected at the same temperature for a queue of metabolomics samples. ICONNMR assists this 
by allowing for a temperature delay when a large number of samples are in the SampleJet queue. For example, a 15 to 60 second delay 
may be inserted prior to data acquisition to allow each sample to equilibrate to the probe temperature. We recommend a 60 second 
delay for both pre- and post-sample insertion to prevent any temperature variation.
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1. Introduction
Nuclear Magnetic Resonance (NMR) spectroscopy is an instrument of choice for drug 
discovery and design (see Fig. 1) [1,2]. For decades, NMR has provided structural details for 
druggable protein targets, and is routinely used for investigating protein-drug interactions 
and conducting high-throughput ligand-affinity screens. In this regards, NMR is able to 
obtain atomic-level resolution of protein-ligand structures in near physiological conditions 
that results in better quality chemical leads [3,4]. Accordingly, NMR has enhanced the 
success rate of the drug discovery process and has made numerous contributions to the 
development of new therapeutics [5-7]. In addition to its role in structural biology, NMR has 
also made significant contributions to the field of metabolomics, especially in the application 
of metabolomics to drug discovery [8-12].
A traditional view of a disease is as a genome or proteome level dysfunction, but there is a 
growing appreciation for the role of metabolomic perturbations in a variety of human 
diseases [13]. For example, an alteration in glucose metabolism is a well-known hallmark of 
cancer (i.e., Warburg effect), but other metabolic changes are also associated with cancer, 
such as glutaminolysis, redox imbalance, and flux changes in the tricarboxylic acid (TCA) 
cycle or the pentose phosphate pathway (PPP). [14]. Similarly, antibiotic resistance in 
Staphylococcus aureus has been shown to result from a re-direction of carbon flow into 
metabolic processes that counter-act antibiotic activity [15,16]. Another example is 
mitochondrial metabolism, especially changes in NAD levels, which is an indicator of aging 
and age-related disorders [17]. The NAD-sirtuin pathway regulates neuronal protection and 
is an important process that prevents axon degradation, which is a primary cause of 
Parkinson’s disease and Alzheimer. Thus, lowered NAD+ levels is a crucial metabolic 
observation in neurodegeneration that is being manipulated for disease prevention [15,17]. 
Thus, the characterization of metabolite levels in any biological system coupled with the 
ability to trace the metabolic fate of individual atoms has the potential to beneficially impact 
a variety of biomedical needs [12]. Specifically, metabolomics is an invaluable tool of drug 
discovery, since metabolic changes may be used to identify therapeutic targets, verify in vivo 
drug efficacy, decipher mechanisms of action, and identify potential toxic side-effects.
The drug discovery pipeline is an extremely resource intensive endeavor. The process is 
time-consuming and may require upwards of twelve years before a new drug obtains FDA 
approval [18]; and costly, with an average expense of $2.6 billion dollars per approved drug 
[19]. The process is also prone to a very high failure rate where only a few lead compounds 
that emerge from traditional medicinal chemistry efforts can be transferred to clinical trials 
[20]. Furthermore, very few drug leads make it past Phase I clinical trials, and most 
compounds eventually fail in Phase III [21]. On average, less than one-in-ten compounds 
receive FDA approval and are launched as a new drug entities [22]. Of course, FDA 
approved drugs are still routinely pulled from the market or encounter safety concerns when 
broadly prescribed [23]. This low overall success rate is a result of numerous problems 
routinely encountered throughout the drug discovery process [24,25]. These problems are 
multifactorial, complex in nature, disease specific, and, in some cases, poorly understood; 
they have also been extensively discussed and reviewed in the literature [26-31]. 
Accordingly, it is well-appreciated that a single technological advancement is not going to 
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resolve the entirety of the challenges facing drug discovery research, but a new approach 
may lead to better chemical leads, to a reduction in toxicity issues, or an improvement in 
selectivity and efficacy. Thus, incorporating NMR metabolomics into a standard drug 
discovery pipeline may lead to an improved success rate, but it won’t solve all of the field’s 
problems.
Metabolomics has the potential to identify therapeutic targets in the drug discovery process. 
First, metabolomics may improve our fundamental understanding of cellular physiology, 
disease development or disease progression, which may lead to the discovery of new 
therapeutic targets. In addition, metabolic profiles resulting from a disease state or drug-
resistance may identify cellular or metabolic processes that are critical to the system. In this 
manner, specific proteins associated with these up-regulated or down-regulated pathways 
may be targeted in either a single drug therapy or as part of a multi-drug treatment. The 
underlying assumption is that the perturbed metabolic processes are required to maintain the 
drug resistance or disease state. Accordingly, inhibiting these proteins may reverse the drug-
resistance or eliminate the disease. Of course, the metabolic profile of a disease state may 
also be used to monitor a response to treatment [32]. The return of the metabolic profile to a 
healthy state would be indicative of a positive therapeutic response. Similarly, a lack of a 
response would suggest an ineffective treatment, and, conversely, a drastic change in the 
metabolic profile may be indicative of a toxic response. Thus, in total, metabolomics may 
beneficially impact all the steps of the drug discovery process, from target identification to 
therapeutic monitoring.
Cancer biology has pioneered the idea of metabolic dysregulation as the source of disease 
pathology. Warburg aerobic glycolysis and glutaminolysis are essential features of cancer 
pathogenesis and are known to occur in most tumors [33]. These metabolic processes are 
potentially linked to oncogene and tumor suppressor regulation [34]. Thus, new therapeutic 
targets to improve cancer management may be based on modulating these altered metabolic 
processes. For example, a new experimental treatment for cancer is 4-phenylbutyrate [35], 
which is a sacrificial metabolite that induces an alternative metabolic pathway to overcome a 
defective urea cycle and repair a nitrogen imbalance. Presumably, 4-phenylbutyrate may 
indirectly address a dysregulated glutaminolysis by facilitating the excretion of glutamine in 
the urine [36]. Specifically, 4-phenylbutyrate is converted to 4-phenylacetate, which then 
reacts with glutamine to form the excretion product phenylacetylglutamine.
In a similar manner, on-going efforts to develop novel cancer treatments by targeting 
metabolic dysregulation (e.g., glycolysis, glutaminolysis, PPP) has highlighted the 
therapeutic importance of metabolic enzymes such as pyruvate dehydrogenase kinase, 
lactate dehydrogenase A, glutaminase 1, thioredoxin reductase and gamma glutamylcysteine 
synthetase [37,38]. In fact, inhibitors developed against all of these metabolic targets are 
currently at various stages of preclinical and clinical trials. Indeed, anti-metabolite 
compounds and enzyme inhibitors are among the most commonly prescribed drugs. For 
example, gemcitabine, a first-line treatment for pancreatic cancer, is a nucleotide 
(metabolite) analog that interferes with DNA synthesis [34]. Notably, gemcitabine resistance 
results from a metabolic shift that increases the cellular production of deoxycytidine 
triphosphate to function as a competitive inhibitor of gemcitabine [34]. Similarly, 
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azathioprine is a purine analog that disrupts RNA and DNA synthesis and is used to treat 
autoimmune diseases like Crohn’s disease and rheumatoid arthritis [39]. Sulfanilamide 
antibiotics inhibit bacterial enzymes that require para-aminobenzoic acid (PABA) for 
synthesizing folic acid, a coenzyme in DNA synthesis. Treatments for inborn errors of 
metabolism are other successful examples of employing metabolite analogs as a therapy 
[40]. Clearly, a metabolic view of disease pathology has beneficially contributed to existing 
drugs and the creation of next generation therapies; and has the potential of significantly 
improving patient outcomes [41].
As illustrated above, NMR-based metabolomics is an asset for drug discovery since it helps 
characterize metabolite level perturbations and altered metabolic pathways that may be used 
to identify protein targets for designing new drugs. NMR is also routinely used as a high-
throughput screen to identify and evolve chemical leads against these protein targets. NMR 
ligand-affinity screens such as SAR-by-NMR, MS/NMR, multi-step NMR, SHAPES, and 
FAST-NMR that make use of saturation transfer difference (STD), WaterLOGSY, 19F NMR, 
HSQC chemical shift perturbations (CSP), transfer NOEs, and fragment-based libraries are 
established means of identifying and validating chemical leads through experimentally-
observed protein-ligand interactions [42-47]. Consequently, combining NMR HTS 
techniques with metabolomics to implement a high content drug screen is a logical next step. 
One such example is the NMR-based metabolomics screen of a library of 56 kinase 
inhibitors targeting eEF-2 kinase and NF-kB [48]. Tiziani et al. monitored global metabolic 
changes resulting from compound treatment to a panel of cancer cell lines (e.g., HeLa, 
CCRF-CEM, SKOV-3, and acute myeloid leukemia (AML) primary cells) in a 96-well 
format. SDS induced cell lysates were then used to collect one-dimensional (1D) 1H CPMG 
and two-dimensional (2D) 1H JRES NMR spectra followed by multivariate statistical 
analysis of the entire spectral dataset. The resulting scores and backscaled loadings plot 
calculated relative to controls were used identify active lead compounds based on the 
magnitude of the metabolic response. Notably, approximately 100 samples were screened in 
less than 24 h.
NMR metabolomics combined with traditional medicinal chemistry can, thus, be used to 
validate in vitro efficacy, selectivity, and specificity while avoiding off target effects (see Fig. 
2). Metabolic perturbations resulting from a drug treatment may be correlated to the 
inhibition of the desired protein-target and/or as a result of unexpected off-target effects 
[49]. If the lead compound inhibits additional protein targets beside the specifically designed 
drug-target, then the lack of selectivity may help predict and anticipate toxicity issues in 
future clinical trials. Thus, medicinal chemistry techniques can then be used to evolve the 
chemical lead in an iterative fashion using insights and feedback from the metabolomics 
experiments. The goal is to maintain the metabolic profile associated with inhibiting the 
desired protein target while diminishing or eliminating metabolic changes resulting from 
unwanted off-target effects. This global approach of monitoring all possible changes to the 
system in response to a drug’s activity would be difficult, if not impossible, to replicate in an 
in vitro setting. Even if the specific off-target proteins could be identified, it is not feasible to 
reproduce the synergistic and simultaneous impact on multiple cellular processes.
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In a similar manner, an in vivo mechanism of action for a new chemical lead may be inferred 
by comparing its induced metabolic profile against metabolic profiles for drugs with known 
mechanisms of action [50]. Compounds that share the same mechanisms of action would be 
expected to have similar impacts on the metabolome. Technological advances have reduced 
NMR analyses times to less than a few mins per sample [51]. Thus, like other secondary-
assays routinely used in a drug discovery pipeline, metabolomics can be applied in a high-
throughput fashion to interrogate an entire library of chemical leads. Accordingly, 
metabolomics is a cost-effective means of filtering-out problematic lead compounds prior to 
expensive clinical trials.
Mechanistic understanding of in vivo drug activity is an important, and, typically, 
challenging stage of the drug discovery process. Knowledge of in vitro and in vivo 
mechanisms of action improves the overall success rate and will beneficially enhance the 
drug design effort [50]. Unfortunately, elucidating a mechanism of action for a specific 
chemical lead may be an arduous, time-intensive and resource-intensive task. Multiplying 
this effort across a large screening library is impractical. Instead, predicting the in vivo 
mechanism of action for new chemical leads by leveraging known entities is a valuable 
alternative to resolving this problem. Furthermore, the availability of a set of drugs with a 
diverse range of biological activities for such a comparison will increase the likelihood of 
successfully assigning a mechanism of action. In addition, identifying compounds that target 
various biological processes and have a range of mechanisms of action may also assist in 
disease management and in combating the emergence of resistance. This may be 
accomplished through a multidrug therapy that combines compounds with distinct modes of 
action. Halouska et al. [50] demonstrated the general approach by comparing the metabolic 
profile of Mycobacterium smegmatis following treatment with a range of antibiotics with 
known mechanisms of action and some promising chemical leads from high-throughput cell-
based screens. 1D 1H NMR spectra combined with multivariate analysis was used to 
characterize the relative global metabolomes. As expected, antibiotics with similar modes of 
action clustered together in the orthogonal projections to latent structures (OPLS) scores 
plot. The high throughput screening (HTS) chemical leads clustered together with known 
cell wall inhibitors implying a similar mechanism of action, which was supported by 
literature reports. It is also possible to invert the protocol and use a drug with a known 
mechanism of action to modulate a metabolic pathway predicted to be important to disease 
progression of drug-resistance. In this manner, if the targeted metabolic pathway is reversed 
following drug treatment and the desired therapeutic outcome is achieved (i.e., cell death) 
then an in vivo mechanism of action is likely indicated. A recent example of this process 
involved a vancomycin intermediate resistant strain of staphylococcus aureus (VISA) that 
exhibited an increase in purine biosynthesis relative to a vancomycin-susceptible strain 
(VSSA) [15]. Treating VISA strains with a combination drug therapy consisting of a sub 
lethal dose of vancomycin and 6-mercaptopurine (i.e., purine substrate analog) led to a 
statistically significant increase in staphylococcal killing. In addition to reversing the 
acquired vancomycin resistance, the metabolomics results also indicate (as expected) that 
the in vivo mechanism of action for 6-mercaptopurine is an inhibitor of purine biosynthesis.
Metabolomics can also provide valuable information during a clinical trial. Metabolomics 
can assist with therapeutic monitoring, drug dosage adjustments, and by differentiating 
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responders from non-responders. Simply, specific metabolic profiles may be attributed to 
each group, which then can be used to classify individual patients by monitoring metabolite 
changes in common biofluids such as urine, serum or fecal material. Another aspect of a 
clinical trial that has benefited from metabolomics is monitoring patient compliance. In this 
regards, patient non-compliance is readily identified by the presence of distinct and/or strong 
signals in the NMR spectrum that are not normally present, such as metabolites from drug 
metabolism or from consuming of caffeine, ethanol or nicotine. As a result of these clear 
benefits to drug discovery, metabolomics continues to be adopted by the pharmaceutical and 
biotechnology industry. A prime example is COMET, the COnsortium of MEtabonomic 
Toxicity [52], which brought together pharmaceutical companies to utilize large datasets of 
NMR metabolomics analysis of urine and serum samples to predict drug toxicity.
To address the expanding interest in NMR metabolomics, we present a detailed, step-by-step 
description of a metabolomics workflow with a specific attention to details important to its 
application to a drug discovery and design process. The protocol includes methods relevant 
to understanding the mechanism of action of novel drug leads in comparison to existing 
therapeutics. Furthermore, we describe the application of metabolomics to wide-variety of 
sample sources commonly encountered in drug discovery programs. This includes bacterial 
and mammalian cell cultures, human and animal tissue samples and different biofluids (e.g., 
urine, serum and fecal material). The entire process from cell culturing and sample 
collection to biological interpretation is described. Importantly, the protocol addresses 
critical concerns regarding the proper: (i) preparation and handling of metabolomics 
samples, (ii) pre-processing, processing and acquisition of spectral data, (iii) metabolite 
identification, and (iv) statistical analysis.
Unlike other OMICS techniques, the composition of the metabolome can easily change from 
the processing, handling, and storage of samples [53]. Metabolites are chemically labile or 
unstable, are subject to thermal degradation or oxidation, and are readily transformed by 
residual enzymatic activity. For example, the oxidation of cysteine and glutathione, or the 
conversion of ATP to AMP (because of a labile phosphate group) are common occurrences 
in metabolomics samples [54]. These biologically-irrelevant sample variations may distort 
our understanding of a system and lead to erroneous conclusions. Accordingly, 
metabolomics requires a robust, efficient, and fast workflow to yield reproducible and 
reliable data. Univariate and multivariate statistical analyses are essential components of any 
metabolomics study and provide the means to interpret the data set and identify the key 
group variances (i.e., metabolite changes) [55]. Nevertheless, issues such as the incorrect 
application of statistical techniques, the subsequent lack of proper model validation, or the 
over-interpretation of models are a common occurrence in the field of metabolomics [56]. 
Accordingly, the protocol presented herein addresses these issues by providing instructions 
to avoid common mistakes.
2. Materials
All samples should be prepared using Nanopure water (H2O) and/or deuterated water (D2O). 
All safety regulations should be followed for the proper handling and disposal of chemicals 
and biological samples used in the study.
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2.1 Laboratory Equipment
1. Bruker AVANCE III HD 700 MHz NMR spectrometer equipped with a 5 mm 
quadruple resonance QCI-P cryoprobe (1H, 13C, 15N, and 31P) with z-axis 
gradients, an automatic tune and match system (ATM), and a SampleJet 
automated sample changer system with Bruker ICON-NMR software (Bruker 
Biospin, Billerica, MA).
2. BSL-2 biosafety level grade hood (e.g., Biological Safety Cabinet, LF BSC class 
2 type A, Thermo Fischer Scientific, Waltham, MA).
3. Nanopure ultra water system (Barnstead Inc., Dubuque, IA).
4. Lab Armor bead bath (Chemglass Life Sciences, Vineland NJ).
5. Incubator capable of maintaining physiological temperature and proper carbon 
dioxide levels (e.g., HERA CELL VIOS 250i CO2 Incubator, Thermo Fischer 
Scientific, Waltham, MA).
6. pH meter and probe.
7. Refrigerated centrifuge capable of speeds up to 21,100 g (e.g., SORVALL micro 
21R centrifuge, Thermo Fischer Scientific, Waltham, MA).
8. Speed Vac for solvent removal (e.g., SAVANT SC210A SpeedVac concentrator, 
Thermo Fischer Scientific, Waltham, MA).
9. Freeze dryer to remove water (e.g., FreeZone 4.5, LABCONCO, Kansas City, 
MO).
10. 1 μL to 1000 μL pipettes
11. FastPrep-96 homogenizer (MP Biomedicals, Santa Ana, CA).
12. ACCU-SCOPE 3030ph microscope (Commac, NY).
13. Cryogenic storage container (Taylor Wharton, Theodor, Al).
14. −80 °C freezer.
15. Flask shaker incubator (up to 250 rpm).
16. Sonic Dismembrator (Sonicator).
2.2 Disposable supplies
1. 1 μL to 1 mL pipette tips.
2. 10 mL aspirating pipettes.
3. 15 mL Falcon tubes.
4. 2 mL Eppendorf tubes.
5. 1 mL screw-cap microcenterfuge tubes.
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2.3 Isotopically Labeled Solvents and Reagents (see Notes 1 and 2)
1. Deuterium oxide (D2O, 99.8 atom %D).
2. 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TMSP-d4, 99.8 atom % 
D).
3. Dimethyl sulfoxide-d6 (DMSO-d6, 99.8 atom %D).
4. 13C6-glucose (99% 13C).
5. 13C2-acetate (99% 13C).
6. Other potential 13C-carbon labeled or 15N-nitrogen labeled reagents.
2.4 Buffers
1. Wash buffer, phosphate-buffered saline (PBS) at pH 7.4: 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4 and 2 mM KH2PO4. To prepare 1 L PBS buffer at pH 
7.4, add 8.0 g of NaCl, 0.2 g of KCl, 2.68 g of Na2HPO4.7H20 and 0.24 g of 
KH2PO4 to a final volume of 1 L of Nanopure water.
2. NMR buffer: 50 mM phosphate buffer at pH 7.2 (uncorrected, see Note 3) in 600 
μL of 99.8% D2O. Add 50 μM (1D NMR experiment) or 500 μM (2D NMR 
experiment) TMSP-d4 as an internal chemical shift reference.
2.5 Cell Media (see Note 4)
1. Dulbecco’s modified eagle medium (DMEM) and Roswell Park Memorial 
Institute (RPMI) medium with the addition of an appropriate amount of fetal 
bovine serum (5 to 20% v/v) and/or supplemental glucose (1 to 25 mM) are 
commonly used to culture mammalian cells.
2. Bacterial cells are typically cultured in complex media, such as like Luria-
Bertani (LB) media for E.coli, Middlebrook’s albumin dextrose catalase media 
(MADC) for Mycobacterium smegmatis, or M9 minimal media.
2.6 Software and Databases
1. Bruker ICON-NMR software for automated NMR data acquisition (Bruker 
Biospin, Billerica, MA).
2. MVAPACK metabolomics toolkit for processing and analyzing chemometric 
data (http://bionmr.unl.edu/mvapack.php) [57].
1.NMR isotope labeled compounds are non-radioactive and do not require any special handling. It is imperative you wear typical 
personal protective gear like gloves and eye protection and follow standard safety protocols.
2.Always keep deuterated solvents in a desiccator or dry box and keep them sealed or wrapped in parafilm while in storage.
3.Typically, metabolomics sample from cell lysates are prepared in 100% D2O and using a standard pH probe may not report pH 
accurately. Standard corrections are pD = pH + 0.4 although Rubinson et al. [92] suggest that phosphate buffer pH is not significantly 
altered to warrant corrections.
4.The choice of culture medium is dependent on the specific needs of the cell type and the specific goals of the experiment. There are 
a variety of cell culture media available either through commercial sources or from published recipes. Also, it may be possible to use 
different media for the same cell type. Again, the choice of medium will be dictated by the specific needs of the experiment. 
Accordingly, only a few representative culture media are listed as illustrative examples, and these are not intended to be an exhaustive 
list.
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3. PCA/PLS-DA utilities for quantifying separation in PCA, PLS-DA and OPLS-
DA scores plots (http://bionmr.unl.edu/pca-utils.php) [58].
4. NMRPipe software for processing and visualizing NMR data (https://
www.ibbr.umd.edu/nmrpipe/install.html) [59].
5. NMRViewJ software for processing and visualizing NMR data (One Moon 
Scientific, Inc. Westfield, NJ; https://nmrfx.org/) [60].
6. R statistical package (https://www.r-project.org/) [44].
7. Chenomx (Chenomx, Inc., Edmonton, AB, Canada) software for automated 
metabolite assignment and quantification from 1D 1H NMR spectra (https://
www.chenomx.com/).
8. MetaboAnalyst software for the statistical, functional and integrative analysis of 
metabolomics data (http://www.metaboanalyst.ca/) [61].
9. Human Metabolomics Database (HMDB) of reference NMR data for known 
metabolites (http://www.hmdb.ca/) [62].
10. Biological Magnetic Resonance Data Bank (BMRB) of reference NMR data for 
known metabolites http://www.bmrb.wisc.edu/metabolomics/) [63].
11. Non-uniform schedule (NUS) generator (http://bionmr.unl.edu/dgs-
gensched.php) for NUS NMR data acquisition [64].
12. Small Molecule Pathway Database (SMPDB) (http://www.smpdb.ca) for 
modeling metabolic pathway changes from list of metabolite changes [65].
3. Methods
Extreme consistency is key to the success of any metabolomics experiment. Accordingly, it 
is essential to apply all experimental protocols and parameters uniformly to all groups in the 
study. Any variation in the preparation, handling or storage of the sample may perturb the 
metabolome and lead to an erroneous results. For example, different sample processing 
times, samples handled by different investigators, cell cultures grown in different incubators 
or shakers, different sources or lot numbers of chemicals, media or disposables, different 
buffer/media preparations (even if the same recipe was prepared by the same individual), are 
all likely to induce a biologically irrelevant-bias in the samples and needs to be avoided. In 
effect, the only difference between groups should be the intended variable (e.g., wild-type 
vs. mutant; treated vs. untreated, healthy vs. disease, etc.). In general, the defined variable(s) 
is expected to induce a measurable change in the metabolome that is detectable by NMR. 
For example, a proper dosage for a drug used in a metabolomics project needs to be 
experimentally determined. The drug dosage needs to be high enough to induce a detectable 
metabolic response, but not too high to induce a generic cell death phenotype (see Note 5).
5.For the success of a metabolomics experiment, cell survival is an essential requirement. This presents a challenge when investigating 
the efficacy, side-effects, mechanism of action or resistance of a drug that impacts cell survival or is designed to kill cells. Similarly, 
cell mutations or experimental conditions (e.g., nutrient depletion, high temperature, anaerobic growth, etc.) that may lead to an 
increase in cell death are also potential problems. The goal is to identify a drug dosage and/or experimental condition that only stress 
the cells, but does not result in any cell death (see section 3.3). In this regard, the observed metabolomic changes will only be a result 
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3.1 Experimental Design
A scientific hypothesis needs to be clearly defined in order to properly design a 
metabolomics experiment (see Fig. 3). In other words, simply characterizing the 
metabolome of a cell, tissue or biofluid is likely to fail to provide any scientific insight or 
value without a logically designed comparative analysis. In this regards, a metabolomics 
experiment is fundamentally a comparison between two or more groups (e.g., control vs. 
drug treated), where a difference or similarity in a metabolome is expected to answer a 
scientific question. The next critical step is to identify an appropriate source for the 
metabolome or the type of biological samples to be compared (i.e., established or primary 
cell lines, tissue samples from an animal model, or human biofluids, etc.). The choice of 
system will then determine the number of biological replicates that can be practically 
obtained, which, in turn, will define the statistical significance of any observed results. 
Given a testable hypothesis and the type of biological samples, there are essentially an 
endless number of experimental variables that can be manipulated, where each permutation 
defines a new group. Practically speaking, it would be impossible to account for every 
possible permutation in a single experimental design. Instead, the identification of which 
groups to use is fundamentally driven by the scientific question the study is designed to 
answer (see Fig. 3) Thus, a general set of protocols is presented for a generic metabolomics 
experiment that can be applied to a drug discovery project. The protocol provides a means to 
determine a drug’s mechanism of action and to monitor a patient’s response to treatment.
The simplest experimental design for a metabolomics drug discovery project will consist of 
two groups: untreated samples and drug-treated samples. Nevertheless, it is typical to 
significantly expand the experimental design beyond just two groups (see Figs. 2 and 3). 
Common groups include:
1. Controls (e.g., wild type cells or healthy subjects).
2. Control with treatment (positive control e.g., wild type cells or healthy animals 
treated with a drug lead).
3. Experimental model (e.g., animal disease model or treatment naïve patients).
4. Experimental model with a drug treatment (e.g., animal disease model or patients 
treated with a drug lead).
5. Negative control (e.g., mutant cells with no treatment, patients with alternative 
disease).
6. Negative control with a drug treatment (e.g., mutant cell lines treated with a drug 
lead).
The metabolomics study may consist of any combination of biological samples originating 
from cell cultures, tissue samples and/or biofluids. Human or animal biofluids may consist 
of urine, serum, plasma, blood, fecal material, saliva, sweat, condensed breath, cerebrospinal 
of the cell’s immediate response to the biological activity of the drug or the experimental condition. Conversely, if the metabolome is 
harvested from a mixture of live and dead cells, then it will be difficult, if not impossible, to deconvolute metabolome changes 
resulting from the stressor or cell death. A correct drug dosage or experimental condition is usually determined by acquiring a series of 
growth curves in which the drug or stressor is titrated over a wide-range of values.
Bhinderwala and Powers Page 10
Methods Mol Biol. Author manuscript; available in PMC 2020 February 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
fluid (CSF) or any other body fluid or excretion. Similarly, tissue samples usually consist of 
organs, such as heart, lungs, brain, liver or kidneys from sacrificed animals. Tissue samples 
from human subjects typically originate from biopsies (i.e., muscle, adipose, etc.), from 
surgeries (i.e., tumors) or tissue banks. Each biofluid, tissue type, or time-point would 
constitute a different group. Of course, there are numerous experimental protocols that could 
also be varied, such as different media, nutrients, temperature, diets, etc.
Besides sample type and experimental protocols, there are other variations that may be 
applied to form additional groups. For example, different groups may be formed by varying 
the drug dosage or by using a placebo. Of course, multiple drugs could be tested in a single 
study and group membership would be defined by what drug a cell culture or an individual 
receives. In addition, the number of drug treatments received by a cohort could vary. Time 
could be another variable in the experimental design (e.g., when samples are collected and 
when treatments are administered). Similarly, different groups may consist of different 
mutant or wild-type cell lines or strains. For example, a mutant cell line may correspond to 
the drug protein target being inactivated (i.e., negative control) through a variety of genetic 
mutations or gene-knockout methods. Alternatively, the mutant cell lines could be various 
human isolates with variable levels of resistance or susceptibility to the tested drug. The cell 
lines could just be different types of bacteria (e.g., E. coli., S. aureus, etc.) or different types 
of cancers (e.g., pancreatic, breast, etc.). Similarly, animal models or human cohorts may 
have different stages or severity of the disease, or even different diseases. Furthermore, 
multiple biofluid samples (i.e., both urine and serum) may be collected from the same 
animal or human participant at multiple time points during the study. Similarly, more than 
one tissue or organ sample may be harvested from each sacrificed animal.
Another important decision regarding the experimental design is the number of biological 
replicates required per group. In general, more biological replicates led to a better statistical 
significance in differentiating between the various groups. But of course, there are practical 
limits to the number of cell cultures, animals or human cohorts that can be prepared or 
recruited for any study. Facility and equipment capacities, the availability of personnel, and 
cost, are all major factors that greatly limit the number of samples or cohorts that are 
possible. There is also an obvious multiplication factor based on the number of desired 
groups and the number of replicates per group. Accordingly, there may be a tendency to 
maximize the number of groups at the expense of the number of replicates per group. This is 
inadvisable since it would likely lead to statistically insignificant conclusions. Instead, the 
number of groups should be reduced to achieve an acceptable minimal number of biological 
replicates per group. In fact, sample size calculation for metabolomics studies is complex 
and not well-defined, where recent efforts suggest sample sizes may need to be > 20 per 
group [66,67]. In the case of metabolomics studies involving human cohorts, the need for 
replicates is even greater and more challenging to estimate, but sample sizes > 60 to 100 
cohorts per group are typical targets.
One final factor to consider for the design of a metabolomics study involving human cohorts 
is the inclusion and exclusion criteria. Simply, what individual characteristics, traits or 
behavior are needed for the goals of the study? Conversely, what are the potential 
confounding factors that may confuse or obscure the desired outcome of the study and 
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should be avoided? The specific inclusion and exclusion criteria are likely unique to each 
study; and there are no general guidelines to apply. Criteria commonly considered include: 
age, body mass index, diet, comorbidities, ethnicity, gender, health test panel (e.g., blood 
pressure, lipid panel, metabolic panel, urinalysis, etc.), physical activity, race, and the use of 
alcohol, recreational drugs, or tobacco (see Table 1).
3.2 Determining Drug Dosage for Cultured Cells
The reported minimum inhibitory concentration (MIC) for a drug against a specific cell 
strain is a good starting point for determining the optimal drug dosage for a metabolomics 
study. Typically, drug concentrations that range between 1 to 24 times the reported MIC or 
MIC50 are tested to identify an optimal drug dosage. The goal is to identify a drug dosage 
that stresses the cells, but does not induce cell death. This is accomplished by identifying a 
drug dosage that results in a decrease in cell growth by approximately 50% (MIC50, see Fig. 
4).
Along with dosage, the time point for administering the drug needs to be experimentally 
determined. First, enough biomass needs to be harvested in order to extract a detectable 
metabolome. Second, the timing of the drug dosage should induce the desired perturbation 
in the metabolome. For example, a particular metabolic processes may only be active during 
a specific phase of the growth curve. Typically, a drug treatment is administered during the 
exponential or log phase for a bacterial culture. The cells are allowed to grow for at least one 
generation or one doubling time before harvesting.
1. Approximately 1 to 20 mM of a stock solution is prepared for each compound to 
be tested by dissolving the required amount of the compound into 0.5 mL of 
ethanol or DMSO-d6 (see Note 6).
2. Bacterial cells are typically grown at 37 °C with shaking at 200 rpm in 50 mL of 
complex or minimal media in a 125 mL Erlenmeyer flask. Mammalian cells are 
typically grown in a 6 well plate with 3 mL of media at 37 °C and 5% percent 
CO2 in an incubator. A total of 21 cell cultures are prepared.
3. The bacterial cells are allowed to grow until an average optical density at 600 nm 
(OD600) of 0.6 is achieved (see Fig. 4). Mammalian cells are grown to 
approximately 40% confluency.
4. Each cell culture receives a different aliquot of the stock drug solution such that 
the final drug concentration ranges from 0 to 24 times the MIC value. Each drug 
dosage is made in triplicate for a total of 21 cell cultures (see Note 7).
5. Following the addition of the drug-leads, the cells are allowed to grow for an 
additional amount of time. This is typically the cell doubling time.
6.The choice of solvent and concentration is determined by the compound’s solubility. The goal is to maximize the concentration of 
the stock solution so as to minimize the amount of solvent that needs to be added to each cell culture. The maximal amount of solvent 
added to a cell culture is 5 to 10 μL.
7.The following range of drug concentrations is typically used: 0x,1x, 2x, 4x, 8x, 16x and 24x the MIC value. The amount of solvent 
(i.e., DMSO-d6 or ethanol) added to any cell culture should be 5 to 10 μL or less.
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6. For bacterial cells, the optical density (OD600) is recorded at the end of the 
additional cell growth time. The growth rate inhibition is calculated by 
comparing the optical density of the treated cells to the untreated cells. Typically, 
untreated cells will reach an OD600 of 1.2 (i.e., a doubling from an initial OD600 
of 0.6), while the OD600 of drug treated cells will be lower. For mammalian cells, 
the cells are visualized under a microscope to measure the percent confluency 
and assess the amount of detached cells [53,68,69]. Typically, untreated cells 
should reach a confluency of approximately 80% (i.e., doubling from an initial 
40% confluency).
7. The desired dosage corresponds to the drug concentration that inhibits cell 
growth by approximately 50% relative to untreated cells (see Note 5).
8. For mammalian cells, an additional consideration is the length of time following 
the drug treatment that is required before the cells can be harvested. It is 
important to provide a significant amount of time to allow a perturbation in the 
metabolome to occur, but it should be short enough to prevent a significant 
accumulation of dead cells. No dead cells are a preferred outcome. After the 
proper drug dosage is identified, repeat experimental steps 2 to 5 with the 
following modifications:
a. A constant drug dosage is used for each replicate cell culture. Each cell 
culture replicate is a different time-point instead of a different drug 
dosage.
b. The time after drug treatment that the cells are harvested are varied 
from zero (i.e., control) to an end-point of approximately 12 to 24 h.
9. For each time point, the percentage of live and dead cells is determined with a 
cell counter. The optimal time point for harvesting the cells would be the latest 
time point following the drug treatment where the vast majority of the cells are 
still alive.
3.3 Determining Drug Dosage for Cohorts.
How a drug is administered (e.g., oral, intravenous, intraperitoneal, etc.), how often the drug 
is administered, how the drug is formulated, and the drug’s dosage will all impact how the 
drug is adsorbed, distributed, metabolized and excreted (ADME) in an animal or human 
[70,71]. This, in turn, will determine both the peak and steady-state concentration of the 
drug; and the resulting efficacy and toxicity of the treatment. Determining the proper drug 
dosage and the route of administering a drug lead for an animal model or a clinical trial is, 
thus, a complex question that is not easily answered. In fact, the entire field of 
pharmacokinetics and pharmacodynamics is dedicated to addressing these very challenging 
questions [72]. Available information, such as a lethal dose (LD50) from cell based assays or 
reported dosages for similar compounds from the scientific literature, may provide initial 
guidance. Unfortunately, there is not a simple algorithm to convert an LD50 to an animal 
dosage. Instead, a detailed efficacy and toxicity study needs to be conducted to determine 
the proper drug dosage prior to embarking on a metabolomics study.
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Drug dosages are typically administered according to a species’ body-mass (e.g., mg/kg). 
Accordingly, it may appear trivial to translate an animal drug dosage to a human clinical trial 
by simply scaling the dosage based on relative body-masses. Unfortunately, this approach is 
incorrect since pharmacokinetics and toxicity issues vary widely across species. Instead, a 
variety of factors, such as differences in allometry, metabolic rates, and physiological, need 
to be considered [73,74]. Thus, the protocol for determining the proper dose and means of 
administering a drug candidate is beyond the intended scope of this chapter.
3.4 Collecting and Storage of Biofluids from Human Cohorts (see Table 1)
1. Human volunteers in a metabolomics study must sign an informed consent form 
before participating.
2. Participants in a metabolomics study are typically required to complete a 
questionnaire that confidentially collects information regarding the individuals 
age, sex, race/ethnicity, residing state, diet (e.g., vegetarian, vegan, etc.), dietary 
restrictions (e.g., no peanuts, no gluten, low-carb, low calorie, no lactose, etc.), 
and a list of daily medications or supplements.
3. Biofluid collection should be done after 12 h of fasting with no fish consumed 
for 24 h [75].
4. Daily supplements and over the counter medications should be stopped at least 
24 h prior to collecting the biofluid(s).
5. Each type of biofluid requires specific and unique collection procedures. For 
example, urine specimens are best collected midstream and in the morning, and 
can be collected by the participant. Conversely, blood needs to be collected by a 
medical professional in a clinical or medical facility. A detailed discussion of 
common protocols employed for collecting biofluids from human and animal 
cohorts is beyond the scope of this chapter, but have been previously described in 
detail [19,53,68,69,76-78].
6. After collecting a biofluid, the samples should be processed immediately, kept on 
ice at all times, and stored at −80 oC.
3.5 Preparation of Mammalian Cells
1. Cell culture media and supplements are obtained from commercial vendors (see 
Section 2.5). The cell culture media may be supplemented with isotopically 
labeled nutrients (e.g., 13C-glucose, 13C-acetate, 15N-ammonium chloride, etc.) 
as dictated by the goals of the experiment (see Section 3.7).
2. Cell culture procedures must follow published guidelines for the cell type to 
avoid misidentification and contamination [79].
3. A minimum target of ten replicate cultures are prepared per group (see Note 8).
8.The number of replicates per group will have a significant impact on the quality of the study and the statistical validity of the 
outcomes. In general, it is best to maximize the number of replicates per group, with a typical target of ten replicates per group. A 
variety of experimental considerations may impact the number of replicates that are practical for a given study. For example, a large 
number of groups may require a reduction in the number of replicates per group. Another consideration is the impact of the number of 
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4. Mammalian cells are typically grown in a 100 mm2 dish with 10 mL of media at 
37 °C and 5% percent CO2 in an incubator. Equally distribute replicates from 
each group between incubators if more than one incubator is required (see Note 
9).
5. The cells are grown until reaching approximately 80 to 90% confluency.
6. The drug is added to the cell culture for the treated groups using the dosage 
determined from Section 3.3. A blank solvent bolus is added to all non-treatment 
groups.
7. The drug is typically added to the cell culture after 80 to 90% confluency. But, 
the drug may also be added at the start of the cell culture or at other time-points 
as required.
8. The cells are harvested after a pre-determined incubation time with the drug.
3.6 Preparation of Bacterial Cell Cultures
1. Perform steps 1–3 from Section 3.5.
2. The drug is added to the cell culture for the treated groups using the dosage 
determined from Section 3.3. A blank solvent bolus is added to all non-treatment 
groups.
3. Typically, the drug is added at the start of the cell culture, but it may be added at 
various points along the growth curve depending on the specific goals of the 
study or the proposed mechanism of action of the drug.
4. Start with a 25 mL culture of cells with an OD600 of 0.05 from glycerol frozen 
stocks.
5. For any type of bacterial cell, it is important to obtain a final OD600 of 20 for the 
entire culture volume. For example, if the total volume is 20mL, then the 
minimum OD600 should be 1.0 per mL. This will ensure that a high quality NMR 
spectrum will be obtained from the cell lysates in a reasonable amount of time.
6. Cell cultures are harvested at a specific time-point of the growth curve (e.g., 
exponential growth, stationary phase, etc.). Important, all cell cultures must be 
harvested at the identical phase of the growth curve, not necessarily the same 
OD600 value.
7. All replicate cell cultures are normalized based on the final OD600 value. The 
total volume for each individual cell culture is adjusted so that each cell culture 
has the same effective OD600 value.
replicates on the quality of the metabolomics samples. Sacrificing quality for a greater number of replicates will not likely lead to a 
successful outcome. Conversely, a limited number of replicates < 4 per group will likely provide meaningless results.
9.In order to avoid the introduction of bias, always randomize sample handling steps. If the samples are always processed in the order 
of the sample number, then a time-bias will be induced across the entire dataset. Instead, if the order is constantly changed at each 
step, the processing time and any impact on the metabolome will be randomized, which in turn will minimize or eliminate any bias.
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3.7 Isotopically Labeled Metabolomics Samples
1. Identify a 13C-, 15N- or other isotopically labeled compound or nutrient to label 
the metabolome and act as a tracer. The tracer should be associated with the 
metabolic pathway of interest and expected to be affected by the experimental 
treatment. 13C6-glucose is a common choice for a tracer since it highlights 
central carbon metabolism (e.g., glycolysis and TCA cycle).
2. The culture media should not contain the selected nutrient or metabolite.
3. The culture media is supplemented with an appropriate molar concentration of 
the tracer metabolite (see Notes 4 and 10). The concentration of the 15N-, or 13C-
labeled metabolite needs to be high enough (≥ 1 to 5 μM) to be detected by 
NMR. Accordingly, the culture media should be supplemented with 
approximately 2.5 to 4 g/L (0.5 to 25 mM) of a major nutrient source like 13C6-
glucose or ~10–100 mg/L of a targeted metabolite like 13C-D-alanine (~ 1 mM). 
Multiple labeled isotopes may be used together if the type of label (13C or 15N) 
differs between the compounds.
4. In general, the isotopically labeled metabolite is added to the culture medium at 
the start of the cell culture. Of course, it may be added at different time points to 
emphasize a specific cellular processes or timed according to the drug treatment.
3.8 Extracting Water Soluble Metabolites from Mammalian Cells
Samples should be stored at −80 °C, but, ideally, samples should be immediately analyzed. 
All samples should be kept on ice or at 4 °C during the extraction process and/or handling. 
There are a few critical aspects to keep note of throughout the process that can affect the 
quality of the resultant data (1) speed, (2) consistency, (3) random processing of samples, 
and (4) the efficient removal of all biomolecules and cell debris [80]. Quick and prompt 
sample processing and preparation are ideal to avoid extended temperature variations, 
chances of environmental contamination and degradation of metabolites. For example, 
protein degradation due to improper shipping processes may lead to alterations in amino 
acid levels in biofluids. Furthermore, metabolites can chemically degrade or transform 
within milliseconds due to enzymatic activity, oxidation, chemical instability, or any number 
of other chemical processes [81]. Thus, rapid inactivation and removal all macromolecular 
cell debris (usually through methanol/ethanol precipitation) that may bind or transform a 
metabolite is a necessary step of the protocol (see Note 11).
10.The experimental conditions for optimal labeling should be experimentally verified for every cell line or cell type used for a 
metabolomics experiment. Factors to consider include the composition of the culture media and the 13C-carbon source (e.g., glucose, 
pyruvate or glutamine) that are used for the cell culture. For mammalian cells, a time course experiment should be conducted where 
cells are cultured from 1 to 48 h to assess the rate of carbon consumption. For bacterial cells, a time course experiment should be 
conducted where cells are cultured for 1 to 3 doubling times to assess the rate of carbon consumption. Examples of media used for 
13C-carbon labeling of mammalian cell metabolome are Dulbecco's Modified Eagle Medium (DMEM) and Roswell Park Memorial 
Institute (RPMI) media. Examples of media used for 13C-carbon labeling of bacterial cell metabolome are Middlebrook’ Albumin 
Dextrose Catalase (MADC) media or M9 minimal media.
11.Removal of proteins and other biomolecules by methanol or ethanol precipitation is preferred over mechanical filtration methods or 
the application of Carr–Purcell–Meiboom–Gill (CPMG) NMR T2 filtering techniques. Filtering techniques are known to impart 
biologically-irrelevant group differences, due to metabolite-macromolecule binding [87].
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1. The extraction process for intracellular metabolites begins after the cells have 
grown to the desired time point. In addition to the cell extract, the media should 
also be analyzed for metabolomics changes as many metabolites get exchanged 
or effluxed outside of the cell.
2. Pre-chill the extraction solvents methanol and methanol:water mixture on dry 
ice.
3. Collect 1 mL of the media and immediately freeze the samples with liquid 
nitrogen and store it at −80 °C until ready for NMR sample preparation.
4. For the cell extracts, wash the cells still attached to the plates twice with 5 mL of 
PBS to remove debris. Discard the wash.
5. Lyse and quench cells with 1 mL of pre-chilled methanol at −20 °C. Incubate 
cells at −80 °C for 15 min. This process should detach the cells from the plate. 
Confirm cell detachment using a microscope and repeat lyse and quenching step 
if necessary.
6. Using a cell scraper, detach and transfer the cell suspension in methanol to a 2 
mL microcentrifuge tube.
7. Centrifuge the 2 mL microcentrifuge tube for 5 min at 15,000 × g and 4 °C to 
pellet the cell debris.
8. Collect the supernatant and transfer to a new 2 mL microcentrifuge tube. Again, 
keep all samples on ice throughout the process.
9. Perform a second extraction, to improve the overall efficiency. Add 0.5 mL of an 
80%/20% mixture of methanol/water prechilled −20 °C to the cell pellet.
10. Centrifuge the suspension of cell debris with 80%/20% methanol/water for 5 min 
at 15,000 × g at 4 °C to pellet the cell debris.
11. Collect the supernatant and transfer it to the 2 mL microcentrifuge tube 
containing the original methanol extract, thereby combining the two extractions.
12. For a third time extract the pellet by adding 0.5 mL of ice cold water.
13. Centrifuge the cell suspension for 5 min at 15,000 g at 4 °C to pellet the 
remaining cell debris.
14. Transfer the supernatant to the original microcentrifuge tube. Combine all 
extractions together in a 2 mL microcentrifuge tube.
15. Repeat steps 1 to 14 for each replicate and for each group either in a randomized 
fashion or at the same time depending on the total sample number and your 
centrifuge capacity (see Note 9).
16. Use a SpeedVac or a rotary evaporator to remove the methanol, chill the 
condenser with liquid nitrogen if using a rotary evaporator.
17. Following evaporation of the methanol solvent, poke a pin hole using a 
thumbtack and flash-freeze the samples in liquid nitrogen.
Bhinderwala and Powers Page 17
Methods Mol Biol. Author manuscript; available in PMC 2020 February 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
18. Freeze dry the samples using a lyophilizer, the pin hole helps establish low 
pressure in each sample tube.
19. Store samples in a −80 °C freezer or proceed to preparing the NMR samples (see 
section 3.11).
3.9 Extracting Water Soluble Metabolites from Gram-Negative Bacteria
1. Spin down the suspension culture at 3200 g at 4°C for 20 min to obtain a pellet.
2. Aspirate the media, keeping 1 mL of the media for NMR analyses.
3. Wash the pellet with ice cold PBS before extraction.
4. Add 1.5 mL of a 1:1 mixture of methanol and water to the pellet and transfer to a 
2 mL microcentrifuge tube
5. Pipet to mix the pellet with a 1:1 mixture of methanol and water prechilled to 
−20 °C.
6. Lyse the cells using a handheld sonicator by pulsing for six 10 s bursts. Take 
precautions to avoid any sample heating during the sonication process.
7. Incubate the microcentrifuge tubes on ice for 2 min to extract the metabolome.
8. Centrifuge at 1000 × g for 10 min at 4 °C to remove cell debris.
9. Collect the supernatant (0.75 mL) and transfer to a new 2 mL microcentrifuge 
tube.
10. Repeat the metabolome extraction by adding 0.75 ml of 1:1 mixture of methanol 
and water prechilled to −20 °C to the cell pellet.
11. Repeat steps 6 to 8 and combine the supernatant with the previous extract.
12. Repeat steps 1 to 11 for all replicate samples and groups (see Note 9).
13. Use a SpeedVac or a rotary evaporator to remove the methanol.
14. Flash-freeze the samples in liquid nitrogen.
15. Remove the water and bring to dryness using a lyophilizer.
16. Store samples in a −80 °C freezer or proceed to preparing the NMR samples (see 
section 3.11).
3.10 Extracting Water Soluble Metabolites from Gram-Positive Bacteria
1. Perform steps 1–5 from section 3.9.
2. Lyse the cells using Matrix B lysing tubes using a FastPrep system. Each sample 
is bead beaten for 45s burst at 1200 rpm for three rounds Take precautions to 
avoid any sample heating during the process.
3. Perform steps 7–16 from section 3.9.
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3.11 Preparation of NMR samples from cell lysates or tissue extracts
1. For 1D NMR experiments, lyophilized cell-free lysates or tissue extracts are 
suspended in 550 μL of 100% 50 mM D2O phosphate buffer at pH 7.2 
(uncorrected, see Note 3) with 50 μM TMSP-d4 as a chemical shift and 
concentration reference.
2. For 2D NMR experiments, lyophilized cell-free lysates or tissue extracts are 
suspended in 550 μL of 100% 50 mM D2O phosphate buffer at pH 7.2 
(uncorrected, see Note 3) with 500 μM TMSP-d4 as a chemical shift and 
concentration reference.
3. Centrifuge the sample at 14,000 g for 10 min to remove any particulates.
4. The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ 
XLS pipette (see Note 12).
5. Repeat steps 1 to 4 for each replicate and for each group (see Note 9).
6. Each sample is added to a 96 well plate SampleJet configuration equilibrated to 
4 °C to prevent metabolite degradation (see Fig. 5).
3.12 Preparation of NMR Samples from Urine
1. Thaw the urine samples stored at −80 oC on ice.
2. Samples are centrifuged at 15,000 × g for 10 min at 4 oC to pellet any 
particulates in the sample.
3. 500 μL of urine is transferred into a new Eppendorf tube and mixed with 50 μL 
of 50 mM phosphate buffer in 99.8% D2O at pH 7.2 (uncorrected, see Note 3). 
50 μM (for 1D 1H NMR) or 500 μM (for 2D NMR) TMSP-d4 are added to each 
sample as a chemical shift and concentration reference.
7. The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ 
XLS pipette (see Note 12).
8. Repeat steps 1 to 7 for each replicate and for each group (see Note 9).
9. Each sample is added to a 96 well plate SampleJet configuration equilibrated to 
4 °C to prevent metabolite degradation (see Fig. 5).
3.13 Preparation of NMR Samples from Serum
1. Thaw the serum samples stored at −80 oC on ice.
2. 500 uL of serum sample is transferred into a new Eppendorf tube and mixed with 
1 mL of methanol to precipitate proteins.
3. Samples are centrifuged at 15,000 × g for 10 min at 4 oC.
12.Smaller diameter NMR tubes of 3 mm (160 μL) or 1.7 mm (45 μL) may be needed if the available metabolomics sample is limited. 
Filling of these smaller diameter NMR tubes may be improved by a liquid handling robot, such as a Gilson 215 Liquid Handler. In 
addition, the NMR acquisition parameters will likely need to be adjusted to account for the lower sensitivity due to the lower number 
of nuclei in the samples.
Bhinderwala and Powers Page 19
Methods Mol Biol. Author manuscript; available in PMC 2020 February 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Transfer the supernatants into new microcentrifuge tubes.
5. Remove the methanol by rotary evaporation using a SpeedVac.
6. The samples are flash-frozen in liquid nitrogen and then dried by lyophilization.
7. The dried samples are reconstituted into 550 μL of 50 mM phosphate buffer in 
99.8% D2O at pH 7.2 (uncorrected, see Note 3). 50 μM (for 1D 1H NMR) or 500 
μM (for 2D NMR) TMSP-d4 are added to each sample as a chemical shift and 
concentration reference.
8. The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ 
XLS pipette (see Note 12).
9. Repeat steps 1 to 8 for each replicate and for each group (see Note 9).
10. Each sample is added to a 96 well plate SampleJet configuration equilibrated to 
4 °C to prevent metabolite degradation (see Figure 5).
3.14 Preparation of NMR Samples from Fecal Matter
1. Thaw the fecal samples stored at −80 oC on ice
2. Weigh 3 to 50 mg of the fecal material in a microcentrifuge tube containing 
matrix D type lysing beads.
3. Add 1 mL of 1:1 water: methanol mixture to extract the metabolome and 
precipitate proteins.
4. Using a FastPrep, bead beat the samples for 30 sec at 1200 rpm thrice.
5. Centrifuged at 15,000 × g for 10 min at 4 oC.
6. Collect the supernatants in a separate microcentrifuge tube.
7. Repeat steps 3–6 to re-extract the pellet and combine both supernatants.
8. Remove the methanol by rotary evaporation using a SpeedVac and water by 
lyophilization
9. Reconstitute in 550 μL of 50 mM phosphate buffer in 99.8% D2O at pH 7.2 
(uncorrected, see Note 3). 50 μM (for 1D NMR) or 500 μM (for 2D NMR) of 
TMSP-d4 will be added to each sample as a chemical shift and concentration 
reference.
10. The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ 
XLS pipette (see Note 12).
11. Repeat steps 1 to 10 for each replicate and for each group (see Note 9).
12. Each sample is added to a 96 well plate SampleJet configuration equilibrated to 
4 °C to prevent metabolite degradation (see Fig 5).
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3.15 NMR Data Collection
All NMR experiments are conducted at 298 K using a Bruker AVANCE III HD 700 MHz 
spectrometer equipped with a 5 mm quadruple resonance QCI-P cryoprobe (1H, 13C, 15N, 
and 31P) with z-axis gradients. An automatic tune and match system (ATM), and a 
SampleJet automated sample changer system with Bruker ICON-NMR software were used 
to automate the NMR data collection (see Fig. 5).
3.15.1 1D 1H NMR
1. Load the NMR metabolomics samples into the SampleJet automated sample 
changer system (see Fig. 5 and Note 9). Check that the SampleJet is in the 
correct mode (i.e., 5 mm tubes).
2. Log into an account on the spectrometer workstation and start the Topspin 
software.
3. The first NMR sample is lowered into the magnet using the Bruker command, sx 
101, where 101 corresponds to sample one in rack one.
4. The spectrometer is locked onto the D2O solvent frequency using the Bruker 
command, lock D2O (see Note 13).
5. The NMR sample is shimmed for optimal signal and suppression of the water 
signal by typing the Bruker command topshim. This will initiate an automated 
gradient shimming procedure, which may take a few min to complete (see Note 
13).
6. The sample is automatically tuned and matched using the ATM system by typing 
the Bruker command, atma.
7. The 90-degree pulse length (μs) is determined by measuring a null spectrum with 
an approximate 360-degree pulse using the Bruker zg pulse sequence (see Note 
14).
8. A 1D 1H NMR spectrum is obtained for each sample using a standard excitation 
sculpting water suppression pulse program (Bruker zgesgp pulse sequence) that 
provides optimal suppression of the residual water signal while maintaining a flat 
baseline (see Note 15).
13.Topshim requires the sample to contain either a D2O or H2O solvent. It is advisable to create a shim file with a parameter set that 
produces an optimal set of shims for your sample type. Read in a shim file using the Bruker command rsh and select the appropriate 
Topshim shim file. If you are doing this for the first time, complete the command topshim, if you are not satisfied with the shim 
performance use command topshim tuneb tunea to obtain an improved set of shims. Write the shim set parameters with the Bruker 
command wsh and save it to a new file name for future reference.
14.The 90 degree pulse length is commonly measured by incrementing the P1 pulse in the zg pulse program by 1 μs or smaller 
increments; and by plotting the relative peak heights or intensities. A maximum peak height should be observed at the pulse length 
corresponding to the 90-degree pulse. Conversely, a minimum or null spectrum should be observed at the pulse length corresponding 
to the 360-degree pulse length. In practice, a more accurate measure of the 90-degree pulse is obtained by measuring the 360-degree 
pulse length and dividing by four to obtain the 90-degree pulse length. A typical 90-degree pulse length for a metabolomics sample 
ranges from approximately 8 μs to 13 μs or longer. Among other factors, the relative salt concentration of the metabolomics sample 
affects the 90-degree pulse, in which a higher salt concentration results in a longer 90-degree pulse. Other factors also contribute to the 
observed 90-degree pulse, so it is always necessary to experimentally determine the 90-degree pulse for each sample or set of samples.
15.Excitation Sculpting parameters (zgesgp) - 32768 data points (TD), SW = 12.02 ppm, O1P (transmitter offset) = 4.70 ppm, D1= 1 
second, NS (number of scans) = 128, DS (dummy/steady state scans) = 16, P1 = 9.5 −13.5 us, SPNAM (shaped pulse for water 
suppression) = SINC1.1000 at 26.39 dB or 0.00228 W.
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9. Typical experimental parameters for a 1D 1H NMR spectrum obtained on a 
Bruker 700 MHz spectrometer with a cryoprobe correspond to 128 scans, 16 
dummy scans, 32,768 data points, a spectral width of 11,160.7 Hz, and a 
relaxation delay of 1.5 (see Note 16).
10. Automated data collection of the entire set of metabolomics samples is 
accomplished using Bruker ICONNMR 5 (see Fig. 5).
11. The sample filename, solvent, pulse program and temperature parameters are all 
defined in Bruker ICONNMR 5 (see Notes 15 to 19).
12. Collect the 1D 1H NMR spectrum for each replicate and each group (see Note 9).
13. The data is processed initially with Topspin to verify spectral quality, but 
exported for further analysis.
3.15.2 2D 1H-13C-HSQC NMR (see Note 20)
1. Follow steps 1 to 7 from section 3.15.1.
2. Using ICONNMR 5, the sample filename, solvent, pulse program and 
temperature parameters are adjusted (see Notes 16 to 19).
3. The ICONNMR setup is similar to a 1D 1H NMR data collection as shown in 
Fig. 5.
4. A standard 2D 1H-13C-HSQC experiment (Bruker hsqcetgpsisp2 pulse program) 
is used to determine the 1H-13C chemical shift correlations for all 13C-labeled 
metabolites in the metabolomics sample (see Note 20).
5. Typical experimental parameters for a 2D 1H-13C-HSQC NMR spectrum 
obtained on a Bruker 700 MHz spectrometer with a cryoprobe correspond to 128 
scans, 32 dummy scans, and a 1.0 s relaxation delay. The spectrum is collected 
with 2 K data points and a spectrum width of 4,734 Hz in the direct dimension 
and 64 data points and a spectrum width of 18,864 Hz in the indirect dimension 
(see Note 21).
16.The NMR data acquisition parameters need to be adjusted to compensate for differences in the field strength and sensitivity of the 
NMR spectrometer actually used for the data collection. Specifically, the number of scans, the number of data points, the sweep-width 
(13.79 ppm, 1H frequency range) and the frequency-offset (centered on water peak at 4.70 ppm) need to be adjusted according to the 
type and configuration of the NMR spectrometer used for the study.
19.Parameters to check before you queue experiments in ICONNMR for 1D 1H NMR are: number of scans ns, number of dummy 
scans ds, 90 degree pulse p1, delay d1, sweep width sw, receiver gain rg, experiment temperature te, and automation setup aunm. We 
recommend using au_zgonly as the automation setup. This will collect all samples at the same receiver gain, which will avoid peak 
intensity variation across the dataset.
20.NMR metabolomics studies are beginning to make use of HMBC, TOCSY, HSQC-TOCSY, 2D J-Resolved spectra, or other 
experiments along with the traditional 2D 1H-13C HSQC approach. Heteronuclear isotope labels like 15N, 31P and other isotope-
labeled metabolites may be detected in addition to 1H- and 13C-labeled metabolites [93]. Accordingly, experimental parameters, data 
processing and preprocessing methods, and data analysis techniques all need to be adjusted to accommodate the specifics of each 
NMR experiment.
21.2D 1H-13C-HSQC parameters (hsqcetgpsisp2) - 1024 data point in F2 and F1, Non-Uniform Sampling at 25%, O1P = 4.7 ppm, 
O2P (offset for 13C) = 75 ppm, NS = 64, DS = 16, d1 =2, P1 = 10 − 13 μs depending on salinity, CPDPRG2 = garp (decoupling 
program), PCPD2 = 55 μs at PLW12 = 4.09 W.
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6. Implementation of fast NMR methods that includes non-uniform sampling 
significantly decreases data acquisition time and/or increases spectral resolution, 
but may introduce artifacts (see Note 22).
7. Collect the 2D 1H-13C-HSQC NMR spectrum for each replicate and each group 
(see Note 9).
8. Process the data initially with Topspin to verify spectral quality, but exported for 
further analysis (see Figs. 6 and 7).
3.16 NMR Data Processing (see Note 23)
All NMR data is processed and analyzed with our MVAPACK software [57], our PCA/PLS-
DA utilities [58], NMRPipe [59], and NMRViewJ [60]. See example processing scripts at 
http://bionmr.unl.edu/wiki/Scripts. Please see the NMRPipe and nmrDraw tutorial (https://
spin.niddk.nih.gov/NMRPipe/doc1/) and NMRViewJ documentation (http://docs.nmrfx.org/) 
for more details.
3.16.1 1D 1H NMR (see Figs. 6 and 8)
1. Apply a 1.0-Hz exponential apodization function to the FID.
2. Fourier transform the FID.
3. The resulting NMR spectrum is automatically simultaneously phased corrected 
and normalized with the phase-scatter correction algorithm [82].
4. Reference the NMR spectrum to the peak of TMSP-d4 (0.0 ppm).
5. Remove the noise and solvent regions manually.
3.16.2 2D 1H-13C-HSQC NMR (see Figs. 7 and 8)
1. Apply a sine-bell apodization function to the t2 dimension.
2. Zero fill the t2 dimension three times.
3. Fourier transform he t2 dimension, manually phase correct, and delete the 
imaginary data.
4. Transpose the data matrix.
5. Apply a sine-bell apodization function to the t1 dimension.
6. Zero fill the t1 dimension three times.
22.Non-uniform sampling of 2D 1H 13C HSQC data can be performed on metabolomics samples albeit with some caution. From our 
experience we recommend no lower than 20% sparsity using the burst augmented scheduler available on http://bionmr.unl.edu/dgs-
gensched.php. Download the sampling schedules as a text file for Topspin. Similarly, processing scripts need to be adapted for NUS 
datasets and a quick guide to that can be found online at http://bionmr.unl.edu/wiki/NUS.
23.A minimalistic approach to the processing of NMR data is optimal for a metabolomics analysis based on multivariate statistics 
models such as PCA and OPLS. The resulting multivariate statistical model is dependent on the choice of processing and 
preprocessing protocols. Baseline corrections and alignment, type of weighting (apodization) function, the type of spectral alignment 
or referencing, the resulting phase correction or phase correction algorithm, the number of zero-fills or the application of linear-
prediction, or any other data manipulation method will affect the outcome of the statistical model. Accordingly, it is best to avoid data 
processing steps since it is difficult to ascertain if the data processing induced a biologically-irrelevant bias to the data or improved the 
model.
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7. Fourier transform the t1 dimension and phase correct manually.
8. Reference the NMR spectrum in both dimensions to the peak of TMSP-d4 (0.0 
ppm).
3.17 NMR Data Preprocessing for Multivariate Modeling
To obtain an accurate and reliable multivariate statistical model, it is essential that the data 
set is properly preprocessed to remove normal systematic variations resulting from 
biological variability, instrument instability, and inconsistency in sample handling and 
preparation. Key preprocessing steps include: (1) alignment, (2) normalization, (3) binning, 
and (4) scaling, which is illustrated in Fig. 9. All NMR datasets are processed with our 
MVAPACK software [82] and our PCA/PLS-DA utilities [58]. See example MVAPACK 
scripts at http://bionmr.unl.edu/wiki/Scripts.
3.17.1 1D 1H NMR
1. Spectra may first be normalized based on either the total cell count or the total 
protein concentration using the BCA (Bicinchoninic Acid) protein estimation 
assay using parallel dishes treated similarly.
2. Normalize the spectra with the PSC algorithm [82].
3. Align and/or bin the spectra. For principal component analysis (PCA), use the 
following parameters:
a. Globally align the spectral data to the peak of TMSP-d4 at 0.0 ppm.
b. Regionally align the spectral data using the icoshift algorithm [83].
c. Bin the spectral data using the adaptive, intelligent binning algorithm 
[84].
4. For orthogonal projection to latent structures (OPLS), use the following 
parameters:
a. Globally align the spectral data to the peak of TMSP-d4 at 0.0 ppm.
b. Regionally align the spectral data using the icoshift algorithm [83].
c. The spectral data are not binned. Instead, use the full-resolution spectral 
data to build the model.
5. Manually remove the solvent peaks and noise regions.
6. Scale the data set using Pareto scaling.
7. Generate the PCA or OPLS model from the data matrix.
3.17.2 2D 1H-13C-HSQC NMR
1. Spectra may first be normalized based on either the total cell count or the total 
protein concentration as explained above.
2. Normalize the spectral data using standard normal variate normalization.
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3. Bin the spectral data using a generalized adaptive, intelligentbinning algorithm 
[84].
4. Pareto scale the data.
5. Generate a PCA or OPLS model from the data matrix.
3.18 Statistical Analysis
Data sets are analyzed with our MVAPACK software [57], our PCA/PLS-DA utilities [58], 
and R [85]. See example MVAPACK and R scripts at http://bionmr.unl.edu/wiki/Scripts.
Improper application of statistical methods is a serious issue in the field of metabolomics, 
which results from some common misconceptions. For example, validation of supervised 
multivariate statistical methods are routinely lacking. Instead, supervised OPLS and PLS 
models need to be validated using a cross validation score like CV-ANOVA [86] and/or 
response permutation testing [87]. R2 and Q2 values, from these supervised models provide 
a measure of model fitness from the original data and a measure of consistency between the 
original and predicted data. R2 and Q2 values do not provide for model validation without a 
proper standard of comparison.
Metabolomics data sets are often described using PCA or PLS/ OPLS models. It is important 
to note that PCA finds the largest source of variance in the dataset irrespective of the intent 
of the study. Separation of clusters observed in a PCA model may not have anything to do 
with a drug treatment if there are other major sources of variance in the data. Thus, a 
loadings plot generated from a PCA model represents all of the variation in the data set, not 
just the expected changes induced by the drug treatment. Supervised methods, like PLS and 
OPLS, address this issue by aggressively forcing group separation based on the defined 
group membership. So, by design, group separation is almost always achieved in a 
supervised model and should not be interpreted as a novel discovery in itself. Again, group 
separation may occur irrespective of the validity of the model. This happens because PLS 
and OPLS models are easily over-fitted, especially for metabolomics data sets since the 
number of variables (e.g., metabolites) are typically larger than the number of replicates. 
This forced separation of groups also contributes to a common misconception in the 
metabolomics community, the incorrect belief that OPLS or PLS out-performs PCA in 
identifying group separation and the underlying dataset variances. Remember, PCA finds the 
largest source of variance in the dataset, so if there is no variance in a PCA model, smaller 
group-specific variations are also not present. Thus, if PCA fails to identify group separation 
it is unlikely that PLS or OPLS will yield a valid model despite the appearance of group 
separation [87]. Simply, PCA, PLS and OPLS generate different models by extracting 
different information to achieve different goals.
PLS and OPLS appear to provide a similar model. In fact, a comparison of PLS and OPLS 
scores plots generated from the same data set may suggest the only difference is a relative 
rotation of the group-defined ellipses. Nevertheless, this apparently subtle change highlights 
a critical difference. PLS intermingles both group-independent and group dependent 
variance; whereas, OPLS places group-independent variance (e.g., confounding factors such 
as differences in diet, age, race, etc.) orthogonal to group-dependent variance. Therefore, a 
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metabolite identified as a major contributor to an OPLS model is strictly the result of the 
defined group difference. Accordingly, we strongly recommend using OPLS instead of PLS.
3.18.1 Univariate Analysis
1. Determine relative metabolite abundances from NMR spectral peak heights 
and/or peak volumes (see Fig. 8).
2. Normalize relative metabolite abundances on a per spectrum basis. One common 
approach is to convert the absolute peak intensities (arbitrary units) to a Z-score:
Z =
Ii − I¯
σ
(1)
where I¯ is the average peak intensity for the spectrum, Ii is the intensity of peak i, 
and σ is the standard deviation of peak intensities. Peak intensities may also be 
normalized to the total number of cells, to the total protein concentration (see 
section 3.17.1), to the average spectral noise, or to an internal standard (see Note 
24). Relative metabolite abundances may also be converted to fold-changes:
F =
Ii
Io
(2)
where Ii is the normalized peak intensity of metabolite i from a treated spectrum 
and Io is the normalized peak intensity of metabolite i from the control or 
untreated spectrum.
3. A standard Student’s t-test is commonly used to determine statistical significance 
only for a pairwise comparison of metabolite changes based on either fold-
changes or normalized peak intensities (see Note 25). A statistically significant 
difference is typically identified by a p-value < 0.05 (see Fig. 8).
4. A Student’s t-test is insufficient for the multiple comparisons that are common to 
a metabolomics study [87,88]. In order to identify the set of metabolites that 
exhibit a statistically significant change, a multiple hypothesis test correction 
method such as a Benjamini-Hochberg [89] or a Bonferroni [90] correction must 
be applied (see Note 25 and 26).
24.For NMR, relative peak intensities are averaged across all replicates per group and for each NMR peak assigned to the metabolite. 
Most metabolites will have more than one peak in an NMR spectrum and commonly all NMR peaks are incorporated into an average 
relative peak intensity. If a metabolite is differentially labeled due to contributions from different pathways, it is then appropriate to 
show single resonances for the metabolite. NMR peaks may need to be scaled by the number of attached hydrogens, since peak 
intensity is proportional to the number of nuclei.
25.There are a wide variety of statistical tests available to analyze the data. Some examples are the Mann–Whitney U test [94], 
Welch’s t-test [95], Hotelling’s t-squared statistic [96], and one-way analysis of variance [87], among others. The proper choice of a 
statistical test depends on several factors. A good introduction to what dictates choice of statistical tests can be found in A Biologist’s 
Guide To Statistical Thinking And Analysis [95].
26.In effect, the uncertainty in each pairwise comparison (as determined by the Student’s t-test) is compounded with the addition of 
each metabolite to a set. The actual p value for a set of metabolites is defined as:
p = 1‐(1‐α)m (3)
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5. A heat-map with hierarchical clustering is commonly generated from the fold-
changes or normalized peak intensities using R (see example R script at http://
bionmr.unl.edu/wiki/Scripts). The heat-map may contain relative metabolite 
abundances for each individual replicate in the study or simply the replicate-
averages for each group (see Note 27).
3.18.2 Multivariate Analysis
1. Generate a PCA and or OPLS model from the data matrix.
2. Fractions of explained variation (R2X and R2Y) are computed during PCA or 
OPLS model training.
3. Internally cross-validate the PCA or OPLS model using seven-fold Monte Carlo 
cross-validation [91] to compute Q2 values (see Note 28).
4. For an OPLS model, compare the Q2 value against a distribution of null model 
Q2 values in 1000 rounds of response permutation testing [87]. Group 
membership is randomly reassigned to generate the set of null models. A p-value 
is calculated from a comparison of the true Q2 value to the set of null model Q2 
values (see Note 28).
5. Further validate the model using CV-ANOVA significance testing, which is used 
to calculate another model p-value [86] (see Note 28).
6. Scores plots (see Figure 6), back-scaled loadings plots (see Figure 8), S-plots 
and/or SUS-plots are often generated from OPLS models.
7. PCA/PLS-DA utilities [58] are used to define group membership by drawing an 
ellipse per group onto the scores plots (see Figs. 6 and 7). Each ellipse 
corresponds to 95% confidence interval for a normal distribution. The PCA/PLS-
DA utilities also generate a metabolomics tree diagram that identifies the 
statistical significance (p-value and/or bootstrap value) and the relative similarity 
of each group in the scores plot (see Fig. 6). The p-value or bootstrap number 
from the pairwise comparison is labeled at each node in the tree.
3.19 Data Analysis - Metabolite Assignment from 1D 1H NMR Data
NMR data are analyzed with NMRPipe [59], NMRViewJ [60], and Chenomx. See example 
scripts at http://bionmr.unl.edu/wiki/Scripts. Please see the NMRPipe and nmrDraw tutorial 
(https://spin.niddk.nih.gov/NMRPipe/doc1/) and NMRViewJ documentation (http://
docs.nmrfx.org/) for more details.
where m is the number of hypotheses (metabolites) and α is typically defined as 0.05. Accordingly, a set of 10 metabolites becomes an 
insignificant p = 0.401 even though each individual metabolite is statistically significant based on a pairwise Student’s t-test with a p < 
0.05.
27.It is more informative to display all replicates from each group in the heatmap. Hierarchical clustering of each replicate is 
indicative of the relative group separation and provides further confirmation of an observed group separation from a PCA, PLS or 
OPLS scores plot.
28.Typical R2 values > Q2 values, and Q2 values > 0.4. While p-values < 0.05 are typically acceptable for a supervised PLS-DA or 
OPLS model. Usually, high quality PLS/OPLS models from metabolomics data sets yield p-values << 0.001.
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1. Perform the identification of metabolites in a 1D 1H NMR spectrum with 
software programs such as Chenomx. Chenomx matches the experimental 1D 1H 
NMR spectrum to a database of 1D 1H NMR spectra of known metabolites. 
Chenomx attempts to explain or describe the experimental NMR spectrum by 
combining or summing as many of the individual reference metabolite NMR 
spectra as needed. In addition to metabolite identification, Chenomx also 
provides an estimate of the metabolite concentration (see Note 29).
2. Upload the 1D 1H NMR spectrum for processing. The NMR spectra can be batch 
processed or processed one at a time.
3. Phase the 1D 1H NMR spectrum.
4. Calibrate and reference the 1D 1H NMR spectrum to TMSP-d4, using the known 
concentration of TMSP-d4.
5. Send the properly phased and calibrated 1D 1H NMR spectrum to the Chenomx 
profiler where the spectrum is compared against the metabolite library.
6. Chenomx will overlay a 1D 1H NMR reference spectrum for each metabolite 
identified in the experimental 1D 1H NMR spectrum. The spectral overlay needs 
to be manually adjusted to optimize the alignment of the experimental 1D 1H 
NMR spectrum with the reference spectrum. Fig. 8 shows an example of a 
labeled 1D 1H NMR spectrum.
3.20 Data Analysis - Metabolite Assignment from 2D 1H-13C-HSQC NMR Data
NMR data are analyzed with NMRPipe [59] and NMRViewJ [60]. See example scripts at 
http://bionmr.unl.edu/wiki/Scripts. Please see the NMRPipe and nmrDraw tutorial (https://
spin.niddk.nih.gov/NMRPipe/doc1/) and NMRViewJ documentation (http://docs.nmrfx.org/) 
for more details.
3.20.1 NMRPipe Processing to Obtain. ft2 and .nv Files.
1. The data files from ICONNMR can be used directly by NMRPipe to process the 
2D 1H-13C-HSQC spectra.
2. On a Linux workstation, open a terminal and go to the directory that contains the 
NMR data. Type bruker to start the NMRpipe software.
3. Read in the experimental parameters file by clicking Read Parameters and verify 
that all the parameters have been correctly updated. Confirm that the mode of 
data collection has been set to echo-antiecho if the NMR spectrum was collected 
with the hsqcetgpsisp2 pulse program.
4. Click Update Script to save an NMRPipe processing script fid.com file in the 
working directory.
29.NMR field strength and sample pH are important aspects of any chemical shift database matching. Thus, we strongly recommend 
performing a chemical shift match with the correct database (e.g., same NMR field strength and pH) while using Chenomx or similar 
software.
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5. Type ./fid.com to start the NMRPipe processing script.
6. When the NMRPipe processing has finished, type nmrDraw to view the 
processed NMR spectrum. Please see the NMRPipe and nmrDraw tutorial 
(https://spin.niddk.nih.gov/NMRPipe/doc1/) for detailed instructions.
7. Phase the NMR spectrum in NMRpipe and note the p0 and p1 values for both the 
1H and 13C dimensions.
8. Edit the NMRPipe processing script hsqcproc.com and replace the parameters 
associated with the NMRPipe phase correction command, ps, with the p0 and p1 
values obtained from step 7.
9. Type ./hsqcproc.com to start the NMRPipe processing script
10. Repeat steps 3 to 9 for each 2D 1H-13C-HSQC NMR spectrum in the dataset. 
This produces a set .ft2 files. One .ft2 file is created for each 2D 1H-13C-HSQC 
NMR spectrum collected for each replicate from each group.
11. Copy all of the .ft2 files into a new folder and use the NMRPipe script 
addnmr.com to generate NMRviewJ files from the .ft2 files. A .nv file will be 
generated for each individual spectrum (.ft2 file) with a numerically incremented 
root name of “Final_”. In addition, the script will combine all of the NMR 
spectra together into a single file called results.nv. The script will also generate 
the text file, rate.txt, which lists all of the individual .nv files (Final_).
3.20.2 Peak Picking and Peak Integration of 2D 1H-13C-HSQC Spectra in 
NMRviewJ
1. Type nmrviewj to start NMRviewJ. Refer to NMRViewJ documentation (http://
docs.nmrfx.org/) for more details.
2. From the Dataset toolbar in the main window, use the Open and Draw Datasets 
function to select the result.nv file.
3. Right click and select attributes to open the attributes window.
4. In the attributes window, select the PeakPick tab.
5. In the blank Lists field in the attribute window, type a filename (i.e., lists) for the 
new peak pick list. Click the Pick button. The software will automatically peak 
pick the displayed spectrum and populate lists with the peak ID number, 
chemical shifts, and intensity.
6. Choose Show Peak Table from the Peak toolbar on the main window. A peak 
table window will open that lists the peak ID, peak intensity and the peak 
chemical shifts.
7. Manually edit the peak list and remove solvent peaks, noise peaks or other 
spectral artefacts. Peaks are deleted from the peak table by using the delete 
function in the PeakPick tab in the attributes window along with the spectrum 
display window. In the spectrum display window, use the mouse to position the 
two cursors around any peak or spectral region to form a box. Then, click the 
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Delete button under the PeakPick tab in the attributes window to remove the 
peak(s).
8. After the peak table has been completely edited, on the peak table window 
choose the Edit tab and select Compress & Degap. Answer yes to the pop-up 
question. This will finalize changes to the peak list and prevent any further edits.
9. On the peak table window choose the Edit tab and then select Save Table. A file 
browser window will open in order to choose a name and location to save the 
new peak list file. The saved peak pick file can be viewed and edited in Excel.
10. In order to obtain peak intensities across the entire set of NMR spectra in the 
dataset, click on the Analysis tab on the main window and select Rate Analysis. 
A set-up window for the Rate Analysis will open.
11. In the Rate Analysis set-up window:
a. Set the Prefix for matrix numbers field to Final_
b. Set the Peaklist field to lists (defined in section 3.20.2 step 5).
c. Make sure Auto fit is checked.
d. Use all other default settings.
e. Click Load time file.
f. In the file browser window, select rate.txt (created in section 3.20.1 step 
11).
g. Click Measure All. The software automatically populates the table in 
the Rate Analysis set-up window with all of the peak intensities across 
the entire NMR dataset.
h. Click Save Table. In the file browser window, save the peak intensities 
table to a new filename (i.e., intensities).
12. The peak list (i.e., list) and the peak intensities (i.e., intensities) files are merged 
in Microsoft Excel using the common peak ID column. The ppm1 (1H ppm) and 
ppm2 (13C ppm) columns are added to the peak intensities columns to generate a 
complete matrix of NMR peaks and intensities across the entire data set.
13. The merged Excel file is saved to a new filename.
3.20.3 Metabolite Assignments from 2D 1H-13C-HSQC Peak Lists
1. The complete list of peaks obtained from the NMRviewJ analyses is searched 
using NMR metabolomics databases such as HMDB [62], BMRB [63], or other 
databases (see Note 30).
2. On the HMDB homepage, choose the Search tab and select 2D NMR Search.
30.BMRB, HMDB and other such databases operate in a similar fashion. Simply upload a peak list with a set of chemical shift 
tolerances and obtain a list of potential matches.
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3. From the Spectra Library pull-down menu, choose 13C HSQC.
4. Cut and paste the 2D 1H-13C-HSQC peak lists into the Peak List field. One set of 
1H and 13C chemical shifts, respectively, per line. Chemical shift values should 
only be separated by white space.
5. Set the 1H chemical shift error tolerance to 0.05 ppm (X-axis Peak Tolerance ± 
field) and the 13C chemical shift error tolerance to 0.10 ppm (Y-axis Peak 
Tolerance ± field).
6. Click the Search button. Depending on the size of the peak list, the software will 
return a ranked-order list of possible metabolites based on the number of 
chemical shift matches to reference spectrum.
7. Manually curate the list of potential metabolite assignments based on the number 
of chemical shift assignments, the quality of the spectral overlap (i.e., chemical 
shift match), number of other metabolites in the same metabolic pathway, and the 
biological system (i.e., is it a reasonable or possible metabolite for the organism),
8. Obtain additional NMR (e.g., HMBC, HSQC-TOCSY) and/or MS spectral data 
to confirm or refute the assignment.
9. An assigned 2D 1H-13C-HSQC spectrum is shown in Fig. 8.
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Fig. 1. 
A schematic diagram outlines the overall drug discovery process and highlights the role of 
NMR and NMR-based metabolomics at every step in the process. Traditional drug discovery 
roles for NMR are boxed in grey, while NMR metabolomics applications are boxed in green.
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Fig 2. 
Cartoon illustrations of hypothetical PCA scores plot for the following scenarios (a) inactive 
compound, (b) active and selective inhibitor, (c) active, nonselective inhibition of target and 
secondary protein, and (d) active, nonselective preferential inhibition of secondary protein. 
Labels correspond to: wild-type cells (wt) and mutant cells (mut). Reproduced with 
permission from Ref 51. Copyright © 2006 American Chemical Society.
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Fig. 3. 
(a) A summary of the design and planning steps in a typical metabolomics-based drug 
discovery project. (b) A workflow for a typical cell-based NMR metabolomics experiment 
focused on understanding the mechanism of action for a chemical lead.
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Fig. 4. 
An example bacterial growth curve for a cell line treated with a drug at an OD600 of 0.6. The 
cellular metabolome should be extracted during the log phase, which captures the majority 
of metabolic variations.
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Fig 5. 
High-throughput sample preparation and data collection. (a) Images illustrating the loading 
of replicate metabolomics samples into the 96 well plate SampleJet configuration. (b) 
ICONNMR screenshots illustrating the stepwise workflow for setting-up a high-throughput 
1D 1H NMR metabolomics screen.
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Fig. 6. 
A representative example of bacterial cells treated with existing drug therapies to decipher 
the in vivo mechanism of action of unknown drugs using 1H NMR based metabolomics. (a) 
2D OPLS-DA scores plot demonstrating the clustering pattern for 12 antibiotics with known 
biological targets and three compounds of unknown in vivo activity: untreated cells (■ 
black), chloramphenicol (♦ teal), ciprofloxacin (♦ orange), gentamicin (♦ pink), kanamycin 
(♦ purple), rifampicin (♦ red ), streptomycin (♦ yellow), ethambutol (▼ green), 
ethionamide (▼ blue), isoniazid (▼ pink), ampicillin (▲ red ), D-cycloserine (▲ purple), 
vancomycin (▲ orange), amiodorone (● purple), chlorprothixene (● green), and 
clofazimine (● red) treated M. smegmatis cells. The ellipses correspond to the 95% 
confidence limits from a normal distribution for each cluster. The untreated M. smegmatis 
cells (■ black) were designated the control class, and the remainder of the cells was 
designated as treated. The OPLS-DA used one predictive component and six orthogonal 
components to yield a R2X of 0.715, R2Y of 0.803, and Q2 of 0.671. (b) Metabolomics tree 
diagram was determined from the OPLS-DA scores plot. The coloring scheme and 
associated symbol for each compound in the tree diagram correlates with colored symbols in 
the OPLS-DA scores plot. The bootstrap numbers for each node are indicated on the tree 
diagram. Reproduced with permission from Ref 52. Copyright © 2012 American Chemical 
Society.
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Fig. 7. 
Metabolomics analysis on the effect of (R,R′)-MNF in PANC-1 cells. (a) PCA scores 
resulting from modeling of the 1D 1H NMR data matrix from untreated PANC-1 cells (open 
symbols) and PANC-1 cells treated with 0.5 μM (R,R′)-MNF (gray symbols) or 1 μM (R,R
′)-MNF (black symbols). A statistically significant degree of separation is observed between 
treated and untreated groups. The ellipses correspond to 95% confidence intervals for a 
normal distribution. Each principal component is labeled with the corresponding R2 and Q2 
values. (b) Bar graph of 1D 1H NMR peak intensities (relative metabolite concentrations) 
resulting from the analysis of PANC-1 cellular extracts after a 1 h incubation with 0.5 μM 
(hatched bars) or 1 μM (filled bars) of (R,R′)-MNF versus untreated cells (open bars). 
Metabolites were identified from the back-scaled loadings plots as the major contributors to 
the group separations in the OPLS models. Benjamini-Hochberg corrected Student's t-test p-
values from pairwise comparisons are indicated. An asterisk indicates significance between 
the control and 1 μM of (R,R′)-MNF while an asterisk with underlying bar indicates 
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significance between the control and both treated groups. (c) Metabolic pathway analysis of 
the identified metabolites found in the 1D 1H NMR spectra of the PANC-1 extracts after 1 h 
incubation with 0.5 μM or 1 μM of (R,R′)-MNF. Each circle represents a matched pathway 
and is colored according to its p values from the pathway enrichment analysis. Statistically 
significant pathways (p < 0.05) are labeled with their common name. (d and e) Targeted 
metabolomics on the effect of 1 μM (R,R′)-MNF on intracellular concentrations of 
carnitine, 1-lactate, and 3-hydroxybutyrate in PANC-1 cells (d) as well as MCF-7 and MDA-
MD-321 breast tumor cells (e). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. Reproduced with 
permission from M. Bernier, J. Catazaro, N. S. Singh, Q. Shi. M. Wang, Q. Yang, A. 
Wnorowski, K. Jozwiak, R. Powers, and I. W. Wainer* (2017) "GPR55 Receptor 
Antagonists Decrease Glycolytic Activity in PANC-1 Pancreatic Cancer Cell Lines and 
Tumor Xenografts", International Journal of Cancer, 141(10):2131-2142 Copyright © 2017 
John Wiley and Sons.
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Fig. 8. 
Examples of a typical (a) 2D 1H-13C HSQC spectrum and (b) 2D 1H-1H TOCSY spectrum 
acquired from bacterial cells. Reproduced with permission from Zhang, B.; Halouska, S.; 
Schiaffo, C. E.; Sadykov, M. R.; Somerville, G. A.; Powers, R. NMR analysis of a stress 
response metabolic signaling network. J. Proteome Res., 2011, 10, 3743- 3754. Copyright © 
2011 American Chemical Society. (c) 1D 1H NMR spectrum acquired from bacterial cells. 
Reproduced with permission from S. Halouska, R. J. Fenton, D. K. Zinniel, D. D. Marshall, 
R. G. Barletta* and R. Powers* (2014) "Metabolomics Analysis Identifies D-Alanine-D-
alanine Ligase as the Primary Lethal Target of D-cycloserine in Mycobacteria", J. Proteome 
Res., 13(2):1065-1076. Copyright © 2014, American Chemical Society. (d) Back-scaled 
loadings plot for 1D 1H NMR spectra showing 15 different metabolites that vary between 
groups. Reproduced with permission from Ref 15. Copyright © 2017 American Society for 
Microbiology. (e) Heatmap showing differences between the vancomycin-susceptible 
Staphylococcus aureus (VSSA) strains and S. aureus with intermediate-level resistance to 
vancomycin (VISA) metabolome. The heatmap was generated by using 2D 1H-13C HSQC 
NMR spectrum-normalized peak intensities of the VSSA or VISA strain, and hierarchical 
clustering is depicted by the dendrogram. The color scale ranges from 0 (red; less intense) to 
1 (green; intense). Statistical significance is denoted by a single asterisk if determined using 
Student’s t test at the 95% confidence level or by two asterisks if determined by Student’s t 
test with a Bonferroni correction for multiple-hypothesis testing. Reproduced with 
permission from Ref 15. Copyright © 2017 American Society for Microbiology.
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Fig. 9. 
Example of an MVAPACK processing script for a 1D 1H NMR dataset. The numbered steps 
in the flow diagram correspond to the numbered lines in the processing script.
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Table 1:
A list of typical exclusion criteria for a metabolomics clinical study
Exclusion Criteria
   •  Acute illness within 2 weeks
   •  Comorbidity (e.g., chronic lung disease, depression, etc.)
   •  Excessive intake of alcohol
   •  Obesity
   •  Pregnant women or menstruating women
   •  Recreational drug use
   •  Risk of transmitting disease through urine (e.g., hepatitis B or C)
   •  Significant abnormalities in clinical chemistry of hematology
   •  Smoker
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